RiteMED Cefepime

Lower resp tract (including moderate to severe pneumonia & bronchitis), uncomplicated & complicated urinary tract (including pyelonephritis), skin & skin structure, complicated intra-abdominal (including peritonitis & biliary tract infections) infections; empiric therapy for febrile neutropenic patients, septicemia.

IV/IM Adult & childn >40 kg Moderate to severe pneumonia 1-2 g every 12 hr for 10 days. Mild to moderate uncomplicated or complicated UTIs including pyelonephritis &/or concurrent bacteremia 500 mg-1 g every 12 hr for 7-10 days. Severe uncomplicated or complicated UTIs including pyelonephritis &/or concurrent bacteremia, moderate to severe uncomplicated skin & skin structure infections 2 g every 12 hr for 10 days. Complicated intra-abdominal infections 2 g every 12 hr in combination w/ metronidazole for 7-10 days. Empiric therapy for febrile neutropenic patient 2 g every 8 hr for 7 days or until resolution of neutropenia. Very severe or life-threatening infections 2 g every 8 hr for 7-10 days, more severe infections may require longer treatment. Childn ≤40 kg Moderate to severe pneumonia 50 mg/kg/dose every 12 hr for 10 days. Mild to moderate uncomplicated or complicated UTIs including pyelonephritis &/or concurrent bacteremia 50 mg/kg/dose every 12 hr for 7-10 days. Severe uncomplicated or complicated UTIs including pyelonephritis &/or concurrent bacteremia, moderate to severe uncomplicated skin & skin structure infections 50 mg/kg/dose every 12 hr for 10 days. Complicated intra-abdominal infections 50 mg/kg/dose every 12 hr in combination w/ metronidazole for 7-10 days. Empiric therapy for febrile neutropenic patient 50 mg/kg/dose every 8 hr for 7 days or until resolution of neutropenia. Very severe or life-threatening infections 50 mg/kg/dose every 8 hr for 7-10 days, more severe infections may require longer treatment. Patient w/ renal impairment or undergoing hemodialysis, CrCl 30-60 mL/min Mild to moderate UTI 500 mg every 24 hr. Mild to moderate infections other than UTI 1 g every 24 hr. Severe infections 2 g every 24 hr. Very severe or life-threatening infections 2 g every 12 hr. CrCl 11-29 mL/min Mild to moderate UTI & other infections 500 mg every 24 hr. Severe infections 1 g every 24 hr. Very severe or life-threatening infections 2 g every 24 hr. CrCl <11 mL/min Mild to moderate UTI & other infections 250 mg every 24 hr. Severe infections 500 mg every 24 hr. Very severe or life-threatening infections 1 g every 24 hr. Continuous ambulatory peritoneal dialysis (CAPD) Mild to moderate UTI 500 mg every 48 hr. Mild to moderate infections other than UTI 1 g every 48 hr. Severe to very severe or life-threatening infections 2 g every 48 hr. Hemodialysis All infections (except febrile neutropenia) 1 g on day 1, then 500 mg every 24 hr. Febrile neutropenia 1 g on day 1, then 1 g every 24 hr.

Hypersensitivity to cefepime, cephalosporins, penicillins, other β-lactam antibiotics.

Cross-hypersensitivity among β-lactam antibiotics. Clostridium difficile-associated diarrhea (CDAD) & colitis. Conditions that may compromise renal function. Life-threatening or fatal encephalopathy, myoclonus & seizures &/or renal failure; neurotoxicity. High risk of severe infection when used as monotherapy. Fall in prothrombin activity. Poor nutritional state, patients in protracted course of antimicrobial therapy & previously stabilized on anticoagulant therapy. Prescribing in absence of proven or strongly suspected bacterial infection or prophylactic indication. May result in overgrowth of nonsusceptible organisms including fungi. False +ve results in urine glucose determinations using cupric sulfate soln (Benedict's reagent, Clinitest). Renal & hepatic impairment. Pregnancy & lactation. Childn <2 mth. Elderly.

GI symptoms & dermatologic/hypersensitivity reactions. Nervous, CV, renal genitourinary, hepatic & hematologic effects; fever, dyspnea, chills.

Increased potential of nephrotoxicity & ototoxicity w/ aminoglycosides. Nephrotoxicity w/ diuretics eg, furosemide.

Cephalosporins

J01DE01 - cefepime ; Belongs to the class of fourth generation cephalosporins. Used in the systemic treatment of infections.

Rx